文献速递临床免疫质量管理与危急值

高性能床旁房水VEGF检测系统的开发及RVO患者概念验证

Development of high-performance point-of-care aqueous VEGF detection system and proof-of-concept validation in RVO patients.
PubMed 文献 · Clin Chem Lab Med · 2023-10-17

研究开发了一种基于磁颗粒化学发光酶免疫分析(MPCLEIA)的自动化床旁房水VEGF检测系统,可在45分钟内用20 μL样本出结果。在57只视网膜静脉阻塞性黄斑水肿(RVO-ME)眼中,房水VEGF-MPCLEIA与基线中央黄斑厚度(bl-CMT)联合模型预测抗VEGF治疗解剖学应答的AUC达0.959。

要点

  • MPCLEIA系统45分钟出结果,仅需20 μL房水样本。
  • VEGF-MPCLEIA与bl-CMT联合模型预测ATR的AUC为0.959。
  • 多因素分析显示VEGF-MPCLEIA(p=0.006)和bl-CMT(p=0.008)与ATR分类显著相关。

核心结论

  • 新型MPCLEIA自动化VEGF检测系统可实现房水VEGF的准确床旁检测,联合bl-CMT有望预测RVO-ME对抗VEGF药物的治疗应答。

研究设计与样本

  • 开发自动化床旁房水MPCLEIA VEGF检测系统,并在57只RVO-ME眼中进行概念验证,分析房水细胞因子联合影像参数对解剖学治疗应答(ATR,相对中央黄斑厚度变化ΔCMT/bl-CMT)的预测价值。

主要发现

  • MPCLEIA系统可在45分钟内用20 μL样本提供结果。
  • ATR与Luminex xMAP平台测定的IL-6、IL-8、MCP-1、VEGF及MPCLEIA测定的VEGF显著相关。
  • 上述标志物的最佳截断值分别为13.26 ng/L、23.57 ng/L、1,110.12 ng/L、105.52 ng/L和85.39 ng/L。
  • 单因素分析显示ATR分类(良好应答为ATR≤-25%,否则为不良应答)与IL-6、IL-8、MCP-1、VEGF-xMAP及VEGF-MPCLEIA显著相关(p<0.05)。
  • 多因素logistic回归显示ATR分类与房水VEGF-MPCLEIA(p=0.006)及bl-CMT(p=0.008)显著相关;VEGF-MPCLEIA联合bl-CMT的回归模型预测ATR分类的AUC为0.959。

关键数值与推荐

  • MPCLEIA系统检测时间45分钟,样本量20 μL。
  • IL-6最佳截断值13.26 ng/L,IL-8为23.57 ng/L,MCP-1为1,110.12 ng/L,VEGF-xMAP为105.52 ng/L,VEGF-MPCLEIA为85.39 ng/L。
  • ATR分类标准:良好应答为ATR≤-25%,否则为不良应答。
  • VEGF-MPCLEIA联合bl-CMT预测ATR分类的AUC为0.959。

临床怎么用

  • 该床旁检测系统有望在RVO-ME患者抗VEGF治疗前快速检测房水VEGF,联合基线CMT辅助预测治疗应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a sensitive point-of-care testing (POCT) aqueous vascular endothelial growth factor (VEGF) detection system, and assess its role for predicting the response to anti-VEGF treatment in macular edema secondary to retinal vein occlusion (RVO-ME) patients. METHODS: An automatic point-of-care aqueous humor Magnetic Particle Chemiluminescence Enzyme Immuno-Assay (MPCLEIA) VEGF detection system was developed. The predictive values of aqueous cytokine levels, in combination with imaging parameters, on anatomical treatment response (ATR, the relative central macular thickness change [ΔCMT/bl-CMT]) were analyzed. RESULTS: The automatic MPCLEIA system was able to provide results in 45 min with only 20 μL sample. Among the 57 eyes with available pre- and post-treatment evaluation, ATR significantly correlated with levels of interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1 (MCP-1) and VEGF measured by Luminex xMAP platform, and VEGF measured by MPCLEIA. Optimal cut-off values for these biomarkers were 13.26 ng/L, 23.57 ng/L, 1,110.12 ng/L, 105.52 ng/L, and 85.39 ng/L, respectively. Univariate analysis showed significant associations between ATR category (good response if ATR≤-25 % or poor response otherwise) and IL-6, IL-8, MCP-1, VEGF-xMAP, and VEGF-MPCLEIA (p<0.05). Multivariate logistic regression revealed that ATR category was significantly associated with aqueous VEGF-MPCLEIA (p=0.006) and baseline(bl)-CMT (p=0.008). Receiver operating characteristics analysis yielded an AUC of 0.959 for the regression model combining VEGF-MPCLEIA and bl-CMT, for predicting ATR category. CONCLUSIONS: Our novel MPCLEIA-based automatic VEGF detection system enables accurate POCT of aqueous VEGF, which shows promise in predicting the treatment response of RVO-ME to anti-VEGF agents when combined with bl-CMT.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhang S, Zhong W, et al. Development of high-performance point-of-care aqueous VEGF detection system and proof-of-concept validation in RVO patients. Clin Chem Lab Med. 2023. PMID: 37843302. doi:10.1515/cclm-2023-0749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。